| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Guidelines recommend beta-blockers and renin-angiotensin-aldosterone system blockers to improve long-term survival in hemodynamically stable myocardial infarction patients with a reduced left ventricular ejection fraction. The prevalence and outcomes associated with beta and renin-angiotensin-aldosterone system blocker therapy in patients with ongoing cardiogenic shock is unknown. In patients with cardiogenic shock lasting more than 24 hours enrolled in Tilarginine Acetate Injection in a Randomized International Study in Unstable Myocardial Infarction Patients With Cardiogenic Shock, we compared 30-day mortality in patients who received beta or renin-angiotensin-aldosterone system blockers within 24 hours of randomization with those who did not. The final study population included 240 patients. A total of 66 patients (27.5%) had either beta blocker or renin-angiotensin-aldosterone system blocker administered within the first 24 hours after the diagnosis of cardiogenic shock. Beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and aldosterone antagonists were prescribed in 18.8%, 10.6%, and 5.0% of patients, respectively. The observed 30-day mortality among patients was higher in patients who received beta or renin-angiotensin-aldosterone system blockers prior to cardiogenic shock resolution. Compared with patients not given beta or renin-angiotensin-aldosterone system blockers, the 30-day mortality was higher among patients treated only with beta-blockers but not among those only treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. The administration of beta or renin-angiotensin-aldosterone system blockers is common in North America and Europe in patients with myocardial infarction and cardiogenic shock prior to cardiogenic shock resolution. This therapeutic practice was independently associated with higher 30-day mortality.
- Guidelines recommend beta-blockers and renin-angiotensin-aldosterone system blockers to improve long-term survival in hemodynamically stable myocardial infarction patients with a reduced left ventricular ejection fraction. The prevalence and outcomes associated with beta and renin-angiotensin-aldosterone system blocker therapy in patients with ongoing cardiogenic shock is unknown. In patients with cardiogenic shock lasting more than 24 hours enrolled in Tilarginine Acetate Injection in a Randomized International Study in Unstable Myocardial Infarction Patients With Cardiogenic Shock, we compared 30-day mortality in patients who received beta or renin-angiotensin-aldosterone system blockers within 24 hours of randomization with those who did not. The final study population included 240 patients. A total of 66 patients (27.5%) had either beta blocker or renin-angiotensin-aldosterone system blocker administered within the first 24 hours after the diagnosis of cardiogenic shock. Beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and aldosterone antagonists were prescribed in 18.8%, 10.6%, and 5.0% of patients, respectively. The observed 30-day mortality among patients was higher in patients who received beta or renin-angiotensin-aldosterone system blockers prior to cardiogenic shock resolution. Compared with patients not given beta or renin-angiotensin-aldosterone system blockers, the 30-day mortality was higher among patients treated only with beta-blockers but not among those only treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. The administration of beta or renin-angiotensin-aldosterone system blockers is common in North America and Europe in patients with myocardial infarction and cardiogenic shock prior to cardiogenic shock resolution. This therapeutic practice was independently associated with higher 30-day mortality. (en)
|
| Title
| - Incidence and Outcomes Associated With Early Heart Failure Pharmacotherapy in Patients with Ongoing Cardiogenic Shock
- Incidence and Outcomes Associated With Early Heart Failure Pharmacotherapy in Patients with Ongoing Cardiogenic Shock (en)
|
| skos:prefLabel
| - Incidence and Outcomes Associated With Early Heart Failure Pharmacotherapy in Patients with Ongoing Cardiogenic Shock
- Incidence and Outcomes Associated With Early Heart Failure Pharmacotherapy in Patients with Ongoing Cardiogenic Shock (en)
|
| skos:notation
| - RIV/00216208:11120/14:43908087!RIV14-MSM-11120___
|
| http://linked.open...avai/predkladatel
| |
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/00216208:11120/14:43908087
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - myocardial infarction; cardiogenic shock; angiotensin II receptor blockers; angiotensin-converting enzyme inhibitors; aldosterone antagonists; [beta]-blockers (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| - US - Spojené státy americké
|
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| |
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| |
| http://linked.open...ain/vavai/riv/wos
| |
| issn
| |
| number of pages
| |
| http://bibframe.org/vocab/doi
| - 10.1097/CCM.0b013e31829f6242
|
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)